Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communication | 12 | 2025 | 569 | 3.520 |
Why?
|
| Physicians | 3 | 2025 | 464 | 1.690 |
Why?
|
| Vaccination | 5 | 2025 | 356 | 1.450 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 432 | 1.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2021 | 686 | 1.260 |
Why?
|
| Qualitative Research | 5 | 2025 | 672 | 1.230 |
Why?
|
| Physician-Patient Relations | 4 | 2025 | 416 | 1.190 |
Why?
|
| Patient-Centered Care | 4 | 2019 | 253 | 1.170 |
Why?
|
| Hospitals | 4 | 2020 | 393 | 1.150 |
Why?
|
| Patients | 2 | 2020 | 111 | 1.110 |
Why?
|
| Decision Making | 3 | 2025 | 402 | 1.020 |
Why?
|
| Quality of Health Care | 3 | 2019 | 517 | 0.980 |
Why?
|
| Health Care Surveys | 3 | 2019 | 285 | 0.810 |
Why?
|
| Focus Groups | 1 | 2024 | 299 | 0.800 |
Why?
|
| Attitude of Health Personnel | 3 | 2025 | 587 | 0.800 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 98 | 0.760 |
Why?
|
| Primary Health Care | 2 | 2024 | 685 | 0.750 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 315 | 0.730 |
Why?
|
| Male | 24 | 2025 | 29546 | 0.720 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 453 | 0.720 |
Why?
|
| Patient Participation | 2 | 2024 | 229 | 0.700 |
Why?
|
| Adult | 13 | 2025 | 16668 | 0.690 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 476 | 0.680 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 432 | 0.680 |
Why?
|
| Humans | 36 | 2025 | 62866 | 0.670 |
Why?
|
| Self-Management | 1 | 2021 | 60 | 0.670 |
Why?
|
| Vaccines | 1 | 2021 | 96 | 0.670 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 352 | 0.660 |
Why?
|
| Aged | 18 | 2025 | 14273 | 0.660 |
Why?
|
| Vaccination Coverage | 1 | 2019 | 8 | 0.650 |
Why?
|
| Noninvasive Ventilation | 2 | 2017 | 70 | 0.650 |
Why?
|
| Middle Aged | 15 | 2025 | 17390 | 0.640 |
Why?
|
| Female | 23 | 2025 | 32560 | 0.630 |
Why?
|
| Mass Screening | 1 | 2025 | 689 | 0.620 |
Why?
|
| Patient Care | 1 | 2019 | 80 | 0.620 |
Why?
|
| Massachusetts | 8 | 2025 | 2061 | 0.620 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 755 | 0.610 |
Why?
|
| Patient Comfort | 1 | 2018 | 2 | 0.610 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 173 | 0.610 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 658 | 0.590 |
Why?
|
| Attitude to Health | 1 | 2020 | 291 | 0.590 |
Why?
|
| Medical Errors | 2 | 2017 | 195 | 0.560 |
Why?
|
| Comprehension | 1 | 2018 | 134 | 0.540 |
Why?
|
| Professional-Family Relations | 1 | 2016 | 88 | 0.480 |
Why?
|
| Hospital Mortality | 3 | 2017 | 867 | 0.460 |
Why?
|
| Length of Stay | 2 | 2017 | 805 | 0.450 |
Why?
|
| Trust | 2 | 2024 | 73 | 0.430 |
Why?
|
| Critical Illness | 1 | 2016 | 321 | 0.400 |
Why?
|
| Inpatients | 1 | 2015 | 302 | 0.380 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 2552 | 0.370 |
Why?
|
| Young Adult | 4 | 2025 | 4656 | 0.350 |
Why?
|
| United States | 9 | 2024 | 7745 | 0.350 |
Why?
|
| Interviews as Topic | 3 | 2017 | 506 | 0.340 |
Why?
|
| Heart Failure | 3 | 2015 | 901 | 0.340 |
Why?
|
| Patient Safety | 3 | 2018 | 242 | 0.340 |
Why?
|
| Activities of Daily Living | 2 | 2021 | 294 | 0.300 |
Why?
|
| Pandemics | 2 | 2025 | 664 | 0.280 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 146 | 0.280 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2652 | 0.270 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2006 | 14 | 0.270 |
Why?
|
| Neoplasms | 1 | 2017 | 1350 | 0.270 |
Why?
|
| Epoprostenol | 1 | 2006 | 15 | 0.260 |
Why?
|
| Acute Disease | 3 | 2017 | 671 | 0.250 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 95 | 0.240 |
Why?
|
| Blood Vessels | 1 | 2006 | 62 | 0.240 |
Why?
|
| Retrospective Studies | 6 | 2020 | 6549 | 0.240 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 171 | 0.240 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 1252 | 0.230 |
Why?
|
| Hospitalization | 4 | 2021 | 1346 | 0.230 |
Why?
|
| Stem Cells | 1 | 2006 | 259 | 0.210 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 77 | 0.210 |
Why?
|
| Quality Improvement | 2 | 2019 | 439 | 0.210 |
Why?
|
| Knowledge | 1 | 2022 | 31 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 5413 | 0.190 |
Why?
|
| Intention | 1 | 2022 | 69 | 0.190 |
Why?
|
| Ecosystem | 1 | 2022 | 55 | 0.190 |
Why?
|
| Disease Progression | 4 | 2019 | 1159 | 0.180 |
Why?
|
| Patient Discharge | 2 | 2017 | 505 | 0.180 |
Why?
|
| Intensive Care Units | 2 | 2016 | 405 | 0.180 |
Why?
|
| Lung | 1 | 2006 | 939 | 0.170 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 33 | 0.160 |
Why?
|
| District of Columbia | 1 | 2018 | 9 | 0.150 |
Why?
|
| Reminder Systems | 1 | 2019 | 74 | 0.150 |
Why?
|
| Maryland | 1 | 2018 | 35 | 0.150 |
Why?
|
| Homes for the Aged | 1 | 2020 | 157 | 0.150 |
Why?
|
| Motivation | 1 | 2021 | 283 | 0.150 |
Why?
|
| Uncertainty | 1 | 2018 | 34 | 0.150 |
Why?
|
| Culture | 1 | 2018 | 77 | 0.140 |
Why?
|
| Health Education | 1 | 2019 | 188 | 0.140 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 221 | 0.140 |
Why?
|
| Calcitonin | 1 | 2017 | 17 | 0.140 |
Why?
|
| Inventories, Hospital | 1 | 2017 | 3 | 0.140 |
Why?
|
| Patient Preference | 1 | 2018 | 83 | 0.140 |
Why?
|
| Nursing Homes | 2 | 2021 | 671 | 0.140 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 18 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 32 | 0.130 |
Why?
|
| Medicare | 1 | 2021 | 614 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 358 | 0.130 |
Why?
|
| Survival Rate | 2 | 2015 | 843 | 0.120 |
Why?
|
| Registries | 1 | 2019 | 877 | 0.120 |
Why?
|
| Homosexuality, Male | 1 | 2015 | 38 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 50 | 0.120 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 46 | 0.120 |
Why?
|
| Adolescent | 2 | 2024 | 6197 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2017 | 337 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 348 | 0.110 |
Why?
|
| Algorithms | 1 | 2019 | 1003 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 143 | 0.110 |
Why?
|
| Comorbidity | 2 | 2015 | 1119 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2017 | 853 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 153 | 0.110 |
Why?
|
| Outpatients | 1 | 2015 | 141 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2017 | 5598 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2014 | 328 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 786 | 0.090 |
Why?
|
| Mortality | 1 | 2012 | 160 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 384 | 0.090 |
Why?
|
| HIV Infections | 1 | 2015 | 964 | 0.070 |
Why?
|
| Telemedicine | 1 | 2012 | 318 | 0.070 |
Why?
|
| Vascular Resistance | 1 | 2006 | 48 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 174 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2006 | 38 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 910 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 93 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 863 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2024 | 258 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2006 | 514 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 3263 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 136 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 5309 | 0.050 |
Why?
|
| Universities | 1 | 2022 | 157 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 1275 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 61 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 177 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 1729 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1115 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 409 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1078 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2015 | 27 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 934 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2015 | 162 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 222 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2017 | 429 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1388 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 67 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 578 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2045 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 975 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2445 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1556 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 727 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1640 | 0.020 |
Why?
|
| Animals | 1 | 2006 | 20612 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 3749 | 0.020 |
Why?
|